Medical Genetics
Kelly A. Avery-Kiejda has not added Biography.
If you are Kelly A. Avery-Kiejda and would like to personalize this page please email our Author Liaison for assistance.
Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells.
Anti-cancer drugs Feb, 2008 | Pubmed ID: 18176116
Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research Mar, 2008 | Pubmed ID: 18310316
Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress.
Cancer research Aug, 2008 | Pubmed ID: 18701495
Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells.
Carcinogenesis Feb, 2009 | Pubmed ID: 18842681
Nucleotide excision repair gene expression after Cisplatin treatment in melanoma.
Cancer research Oct, 2010 | Pubmed ID: 20807809
BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Breast cancer research and treatment Jun, 2011 | Pubmed ID: 21409391
P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation.
BMC cancer , 2011 | Pubmed ID: 21615965
Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
International journal of cancer Jan, 2014 | Pubmed ID: 23824750
Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
PloS one , 2013 | Pubmed ID: 23940574
STaRRRT: a table of short tandem repeats in regulatory regions of the human genome.
BMC genomics , 2013 | Pubmed ID: 24228761
The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome.
Carcinogenesis Mar, 2014 | Pubmed ID: 24336193
Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer.
BMC cancer , 2014 | Pubmed ID: 24479446
The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer.
BMC cancer , 2014 | Pubmed ID: 24725360
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value.
Nature communications , 2015 | Pubmed ID: 25641231
Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis.
Molecular & cellular proteomics : MCP Sep, 2015 | Pubmed ID: 26041846
Novel genes associated with lymph node metastasis in triple negative breast cancer.
Scientific reports , 2015 | Pubmed ID: 26537449
The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low Δ40p53:p53 ratio and better outcome.
Carcinogenesis Jan, 2016 | Pubmed ID: 26586794
MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer.
International journal of molecular sciences , 2015 | Pubmed ID: 26633365
A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer.
Endocrine connections May, 2016 | Pubmed ID: 27090263
A novel polymorphic repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is not associated with the risk of developing breast or endometrial cancer.
BMC research notes , 2016 | Pubmed ID: 27230222
The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer.
Breast cancer research and treatment Nov, 2018 | Pubmed ID: 30430302
ACERCA DE JoVE
Copyright © 2024 MyJoVE Corporation. Todos los derechos reservados